Home > Insider Trading > Filing (0000899243-20-015623)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1680581	Fulcrum Therapeutics Inc.	FULC	Pharmaceutical Preparations (2834)	474839948

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1778713	Diego Cadavid	C/O Fulcrum Therapeutics, Inc. 26 Landsdowne Street Cambridge MA 02139	Svp Clinical Development	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-06-04	226	$4.83	67,011	No	4	M	Direct
Common Stock	Disposition	2020-06-04	226	$20.05	66,785	No	4	S	Direct
Common Stock	Acquisiton	2020-06-05	451	$4.83	67,236	No	4	M	Direct
Common Stock	Disposition	2020-06-05	451	$20.18	66,785	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2020-06-04	226	$0.00	226	$4.83
Common Stock	Stock Option (right to buy)	Disposition	2020-06-05	451	$0.00	451	$4.83

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
14,588		2028-07-10	No	4	M	Direct
14,137		2028-07-10	No	4	M	Direct

Footnotes

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.01 to $20.10, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.04 to $20.31, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
The shares underlying the option are scheduled to vest in equal quarterly installments from July 16, 2018 through July 15, 2022.